Novavax (NVAX) Resumen de Acciones
Novavax, Inc. es una empresa biotecnológica dedicada al descubrimiento, desarrollo y comercialización de vacunas para prevenir enfermedades infecciosas graves en Estados Unidos, Europa y el resto del mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
NVAX Community Fair Values
Create NarrativeSee what 101 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Novavax, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$8.98 |
| Máximo en las últimas 52 semanas | US$11.97 |
| Mínimo de 52 semanas | US$6.13 |
| Beta | 2.37 |
| Cambio en 1 mes | 5.77% |
| Variación en 3 meses | -2.39% |
| Cambio de 1 año | 23.18% |
| Variación en 3 años | 30.33% |
| Variación en 5 años | -94.04% |
| Variación desde la OPV | -88.78% |
Noticias y actualizaciones recientes
Recent updates
Seeking Alpha • May 12
Novavax: Betting On This Vaccine Maker's Turnaround Story, After Pfizer Deal
Summary Novavax receives a Hold rating, reflecting neutral fundamentals despite a Q1 earnings beat and strong recent price momentum. NVAX's upside hinges on executing strategic partnerships, notably with Pfizer, and advancing its vaccine pipeline amid sector tailwinds from infectious disease outbreaks. Profitability remains elusive, with negative equity and choppy cash flow; consensus expects no positive EPS until at least 2028. Valuation implies nearly 40% upside to Wall Street's $14.11 target, but technicals and seasonal demand volatility temper conviction in a sustained rally. Read the full article on Seeking Alpha
Actualización de narrativa • Apr 26
NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand
Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.Actualización de narrativa • Apr 11
NVAX: Bearish View Will Hinge On Future COVID Demand Execution
Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.Actualización de narrativa • Mar 28
NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions
Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.Actualización de narrativa • Mar 14
NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution
Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.
Actualización de narrativa • Feb 27
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.Artículo de análisis • Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...Actualización de narrativa • Nov 08
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.Actualización de narrativa • Oct 24
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.Actualización de narrativa • Sep 04
Global Vaccine Market Will Unlock Upside Despite Execution Risks
Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.Artículo de análisis • May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...Seeking Alpha • Apr 28
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Summary Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves, yet uncertainties in its COVID-19 vaccine remain. NVAX stock's rating maintained at "Hold" despite ongoing hurdles based on improved cash position and potential future opportunities. Investors should remain cautious, balancing optimism with awareness of persistent risks and market volatility. Read the full article on Seeking Alpha
Nueva narrativa • Apr 22
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Seeking Alpha • Apr 11
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Summary Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet 20%. FDA approval delay for Nuvaxovid jeopardizes a crucial $175M milestone payment, though Novavax has the financial flexibility to survive this setback. Despite significant regulatory and competitive risks, NVAX stock maintains a "Hold" rating as a speculative component for barbell portfolios. Read the full article on Seeking AlphaArtículo de análisis • Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Novavax, Inc. ( NASDAQ:NVAX ) shareholders that were waiting for something to happen have been dealt a blow with a 28...Artículo de análisis • Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Novavax, Inc. ( NASDAQ:NVAX ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jan 16
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Summary I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi offers significant benefits but does not assure it of ongoing success. My analysis remains cautious, emphasizing the need for careful consideration of Novavax's long-term viability and strategic moves. Read the full article on Seeking AlphaArtículo de análisis • Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...Artículo de análisis • Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Novavax, Inc. ( NASDAQ:NVAX ) defied analyst predictions to release its third-quarter results, which were ahead of...Seeking Alpha • Nov 13
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Summary Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite effective products, reduced guidance and restructuring uncertainty make NVAX stock a hold, with the Sanofi partnership and upcoming milestones as a potential bullish catalyst. Read the full article on Seeking AlphaArtículo de análisis • Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Novavax, Inc. ( NASDAQ:NVAX ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 31
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Summary Novavax' Q3 earnings are due on 6th November. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine. Novavax succeeded, but Nuvaxovid came to the market too late to build market share and the company ended up making heavy losses. Sanofi has acquired the rights to nuvaxovid, paying Novavax $500m upfront, and will look to develop a COVID / Influenza combo vaccine using Novavax' technology. Unfortunately, Sanofi milestones and revenues aside, that leaves Novavax with few opportunities to generate revenue, which likely means its valuation will fall over time. Read the full article on Seeking AlphaSeeking Alpha • Sep 01
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Summary Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant, but newer Omicron variants have outpaced it, limiting competitive advantage. Financial stability hinges on achieving key milestones in the Sanofi partnership and successful commercialization of new vaccines. Despite the Sanofi deal, maintaining a "hold" position is prudent given the high-risk nature of Novavax's future prospects. Read the full article on Seeking AlphaArtículo de análisis • Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Novavax, Inc.'s ( NASDAQ:NVAX ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...Seeking Alpha • Aug 13
Novavax: Staying Long Despite Coming Up Short In Q2
Summary Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider. I discuss my updated NVAX strategy. Read the full article on Seeking AlphaSeeking Alpha • Jul 26
Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Summary Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning potential, making it reliant on revenue streams from Sanofi. Novavax's long-term prospects may be challenging as it may struggle to develop new products and could see its revenue streams dry up post-2025. In this review ahead of Q2 earnings (to be announced on August 6) I take a deeper look at the Sanofi deal, and what to expect from Q2 earnings. Read the full article on Seeking AlphaRentabilidad de los accionistas
| NVAX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -4.0% | -3.0% | -0.3% |
| 1Y | 23.2% | 32.9% | 26.7% |
Rentabilidad vs. Industria: Los resultados de NVAX fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 32.9% el año pasado.
Rentabilidad vs. Mercado: NVAX obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.7% el año pasado.
Volatilidad de los precios
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: NVAX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NVAX (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 749 | John Jacobs | www.novavax.com |
Novavax, Inc, empresa de biotecnología, se dedica al descubrimiento, desarrollo y comercialización de vacunas para prevenir enfermedades infecciosas graves en Estados Unidos, Europa y a escala internacional. La empresa comercializa Nuvaxovid, una vacuna COVID-19; y la vacuna contra la malaria R21 Matrix-M adyuvada. Tiene acuerdos de licencia y colaboración con Sanofi, Pfizer Inc, Takeda Pharmaceutical Company Limited y Serum Life Sciences Limited para el desarrollo, fabricación y comercialización de la vacuna COVID-19.
Resumen de fundamentos de Novavax, Inc.
| Estadísticas fundamentales de NVAX | |
|---|---|
| Capitalización bursátil | US$1.52b |
| Beneficios(TTM) | -US$87.83m |
| Ingresos (TTM) | US$596.34m |
2.5x
Ratio precio-ventas (PS)-16.8x
Ratio precio-beneficio (PE)¿Está NVAX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NVAX | |
|---|---|
| Ingresos | US$596.34m |
| Coste de los ingresos | US$432.38m |
| Beneficio bruto | US$163.96m |
| Otros gastos | US$251.79m |
| Beneficios | -US$87.83m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.53 |
| Margen bruto | 27.49% |
| Margen de beneficio neto | -14.73% |
| Ratio deuda/patrimonio | -201.0% |
¿Cómo se ha desempeñado NVAX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 23:04 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Novavax, Inc. está cubierta por 24 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |